For research use only. Not for therapeutic Use.
Aderamastat (FP-025) is an orally active matrix metalloproteinase 12 (MMP-12) inhibitor. Aderamastat can be used for the research of asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis[1].
| Catalog Number | I040525 |
| CAS Number | 877176-23-3 |
| Synonyms | 5-[3-[4-[(3-methylphenyl)methoxy]phenyl]sulfanylfuran-2-yl]imidazolidine-2,4-dione |
| Molecular Formula | C21H18N2O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C21H18N2O4S/c1-13-3-2-4-14(11-13)12-27-15-5-7-16(8-6-15)28-17-9-10-26-19(17)18-20(24)23-21(25)22-18/h2-11,18H,12H2,1H3,(H2,22,23,24,25) |
| InChIKey | CXEKSVVDMIAMLF-UHFFFAOYSA-N |
| SMILES | CC1=CC(=CC=C1)COC2=CC=C(C=C2)SC3=C(OC=C3)C4C(=O)NC(=O)N4 |
| Reference | [1]. Li, Yuhua, et al. Safe administration of MMP-12 inhibitor. Patent. WO2022261624 A1. |
